Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (March 2021)
18 slides from Noxopharm's investor presentation, March 2021
Slide 1: Updated Corporate Presentation February/March 2021
Noxopharm Limited (ASX:NOX) UPDATED CORPORATE PRESENTATION February/March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 2: Disclaimer
Disclaimer This presentaIon has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectaIons reflected in the forward looking statements be considered as an offer or invitaIon to subscribe for, or purchase any shares in NOX, or as an include
Slide 3: Latest News
Latest News IONIC TRIAL. IONIC study submi]ed for ethics approval. Trial DARRT-2 TRIAL. Study LuPIN TRIAL. Major expanded into wide range of cancer conference hears expected to commence following paIent screen cancers. Hospital selecIon NOX + Novartis drug for mulInaIonal study being combination del
Slide 4: Veyonda breakthrough multiple-acting immunotherapy drug
Veyonda® breakthrough mul5ple-ac5ng immunotherapy drug Blocks autophagy AcIvates increasing immune immune cells acIvaIon Inhibits Increases inflammaIon trafficking of activated immune cells Source: Dana-Faber Cancer Institute Converts COLD tumors to HOT tumors NOXOPHARM LIMITED (ASX:NOX) 4
Slide 5: Veyonda Clinical program
Veyonda® Clinical program LuPIN-1 Phase I/II trial Veyonda + 177Lu-PSMA (NovarLs) IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy NOXCOVID-1 Phase Ib trial Veyonda NOXOPHARM LIMITED (ASX:NOX) 5
Slide 6: The focus of this presentation
Short- to medium-term poten1al partnering opportuni1es The focus of this presentation LuPIN-1 Phase I/II trial Veyonda + 177Lu-PSMA (NovarLs) IONIC-1 Phase I/II trial Veyonda + Opdivo® (Bristol Myers Squibb) DARRT-2 Phase II trial Veyonda + external radiotherapy NOXCOVID-1 Phase Ib trial Veyonda NOX
Slide 7: LuPIN
LuPIN Veyonda® + 177lutetium-PSMA-617 An exciting new treatment for prostate cancer NOXOPHARM LIMITED (ASX:NOX) 7
Slide 8: LuPIN (Veyonda + Lu-PSMA-617)
LuPIN (Veyonda + Lu-PSMA-617 177luteLum-PSMA-617. Acquired by NovarIs (4th largest pharma company/US$195 billion market cap) in 2018 for US$6 billion Lu-PSMA-617 is a radioacIve drug injected IV and designed to deliver radiaIon to every prostate cancer cell throughout the body A proposed new treatme
Slide 9: LuPIN Study
LuPIN Study QUESTION: would adding Veyonda boost the effecIveness of the NovarIs drug, with more men responding as well as achieving significantly longer survival Imes? Phase I/II study. St Vincent’s Hospital Sydney. Prof Louise Emme] 56 men. Late-stage cancer. No remaining standard treatments. AnIcip
Slide 10: LuPIN: Interim Data Reporting
LuPIN: Interim Data Reporting American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021 ANSWER: Yes, the combination of Veyonda and Lu-PSMA-617 looks to considerably more effective than Lu-PSMA-617 on its own (based on published Phase 2 data1) 56 men Median Overall Surviva
Slide 11: LuPIN: Interim Survival Data
LuPIN: Interim Survival Data Median overall survival = time when half the patients have died and half still alive Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaIc Historical data1 ~ 4.5 months 177 Lu-PSMA-617 alone2 13.3 months 177 Lu-P
Slide 12: Potential opportunities for LuPIN
Poten5al opportuni5es for LuPIN LuPIN Study Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaIc VISION Study NovarIs preferred treatment opIons1 1. NovarIs Oncology Pipeline Update June 2020 NOXOPHARM LIMITED (ASX:NOX) 12
Slide 13: IONIC
IONIC Veyonda ® + nivolumab (Opdivo®) Overcoming resistance to checkpoint inhibitors NOXOPHARM LIMITED (ASX:NOX) 13
Slide 14: IONIC Study
IONIC Study Phase I/II pilot proof-of-concept study 15 patients treated with 15 patients with cancers Opdivo where tumours considered resistant to Opdivo not responsive • Melanoma All other cancer types • Lung • Kidney Typically 0-3% response rate • Bladder • Head & neck Veyonda + Opdivo 10-30% resp
Slide 15: Other Updates
OTHER UPDATES DARRT-2 trial SelecIon of clinical sites almost completed. LuPIN trial Study ends Oct 2021. Final Report expected Q1 2022 NOXCOVID trial Part 2 to start 1st March 2021. Drug pipeline First-in-class drug with novel approach to treatment of brain cancer progressing well NOXOPHARM LIMITED
Slide 16: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity Programs focusing on immuno-oncology and cell therapy remain the
Slide 17: Key metrics
Key metrics as at 19 February 2021 Market cap A$210m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paIent recruitment Share price A$0.79 • COVID-19 clinical trial compleIon • Growing first-in-class drug pipeline Issued cap ~266m shares • Pharmorage (subsidiary) progressing novel drug developm
Slide 18: For further information
For further informa.on email: info@noxopharm.com web: www.noxopharm.com twi\er: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 18